Phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), and clinical activity of the antibody-drug conjugate (ADC) ARC-02 as monotherapy and in combination with rituximab in adults with B-cell non-Hodgkins lymphoma (NHL)